Alexandra Sokolova

Data from Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer

Martin Smoragiewicz, Alice Bernard‐Tessier, Mark Linch, John Shen et autres

Abstract Purpose: Resistance to androgen receptor (AR) pathway inhibitors necessitates the development of regimens to improve outcomes in metastatic prostate cancer (mPC). This phase Ib clinical trial evaluated the safety/tolerability and pharmacokinetics of bavdegalutamide, an oral proteolysis-targeting chimera AR degrader, combined with …

Supplementary Data 1 from Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer

Martin Smoragiewicz, Alice Bernard‐Tessier, Mark Linch, John Shen et autres

Supplementary Appendices, Tables, and Figures.

Prospective prostate cancer screening in germline pathogenic variant carriers: The PATROL study.

D C Lee, Caitlin Orr, Evelyn Milavsky, Andrew Amini et autres

10505 Background: Germline pathogenic variants (gPV) in prostate cancer (PCa) risk genes are associated with aggressive disease, but optimal screening thresholds for this population are unclear. We report early results from the Prostate Cancer Screening for People at Genetic Risk for Aggressive …

us (code pays fourni par la source)

Initial findings from the PROMISE Registry, a US decentralized, prospective prostate cancer genetic registry.

Heather H. Cheng, Justin Lorentz, Andrew J. Armstrong, Hala Borno et autres

10610 Background: The role for genetic testing (GT) for prostate cancer (PCa) patients (pts) has expanded to find pts with germline pathogenic variants (PV) for therapeutic opportunities given FDA-approvals for PARP inhibitors in metastatic PCa as well as understanding familial cancer risk …

us, ca (code pays fourni par la source)

Genomic predictors of response to cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): A real-world analysis from the PROMISE registry.

Peter D. Zang, Nicholas Henderson, Deepak Kilari, Vadim S. Koshkin et autres

5066 Background: Cabazitaxel (Cabazi) is an important treatment for refractory mCRPC, but responses are heterogeneous. Homologous recombination repair (HRR) and tumor suppressor gene (TSG alterations (alt) can predict aggressive behavior in patients (pts) with mCRPC. We hypothesize that Cabazi has enhanced efficacy …

us (code pays fourni par la source)

IP43-17 THE UTILITY OF ENHANCED SCREENING FOR PEOPLE WITH INHERITED RISK OF DEVELOPING AGGRESSIVE PROSTATE CANCER IN THE PATROL STUDY

Keyan Salari, Andrew Amini, Rajveer Kaur, Margaret R. O'dea et autres

Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations

Heather H. Cheng, Sam Callis, Evan Y. Yu, Scott E. Delacroix et autres

us (code pays fourni par la source)

Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer

Deepak Kilari, Nicholas Henderson, Kyra Yamamoto, Ye Yao et autres

PURPOSE Previous studies suggest that SPOP mutations result in increased sensitivity to androgen receptor pathway inhibitors (ARPIs) but are limited by lack of granular data. We hypothesize that SPOP mutations are associated with improved outcomes across the spectrum of advanced prostate cancer …

us (code pays fourni par la source)

Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617

Justine Panian, Nicholas Henderson, Daniel Herchenhorn, Pedro C. Barata et autres

BACKGROUND: 177Lu-PSMA-617 is approved for patients with metastatic castration-resistant prostate cancer (mCRPC). Although treatment is associated with improved outcomes, not all patients benefit and response is heterogeneous. We aim to characterize genomic alterations associated with benefit to 177Lu-PSMA-617. MATERIALS AND METHODS: This …

us (code pays fourni par la source)

Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry

Stacy Loeb, Scott W. Keith, Laura Gross, Rebecca Hartman et autres

PURPOSE: Prostate cancer (PCA) germline testing (GT) informs precision therapy, cancer screening, and hereditary cancer risk for patients and families. To support patient-centered PCA GT, studying patient-reported outcomes (PROs) is essential. METHODS: PROGRESS was a national patient-driven registry (January 2021-April 2022) for …

us (code pays fourni par la source)

Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients

Maliha Tayeb, Emanuel Barrett, Tara Al-Saleem, Pranavi Kondam et autres

Abstract Importance Pathogenic germline variant (PGV) rates in cancer risk genes and their association with clinical pathological features inform genetic testing practices for prostate cancer (PCa) patients. Objective To determine the rate of PCa risk gene PGVs in a real-world, diverse cohort …

us (code pays fourni par la source)

Barriers to germline genetic testing in advanced prostate cancer: Survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (PCCTC).

Alexandra Sokolova, Channing J. Paller, Emmanuel S. Antonarakis, Pedro C. Barata et autres

e17073 Background: The NCCN began recommending germline genetic testing for individuals with high-risk or advanced prostate cancer (PCa) in 2017. In 2019, our survey of physicians within the PCCTC showed that the adoption of germline testing was not widespread: 62% of physicians …

us, gb (code pays fourni par la source)